Lung cancer is responsible for 12.9% of all new cancer cases diagnosed globally and is responsible for 19.5% of all cancer-related deaths. The percentage of patients presenting as stage IV disease increased from 38.7% between 1994 and 1998 to 47.2% between 1999 and 2004 to 54.8% between 2008 to 2017. Histology has been found to be prognostic for survival in stage 4 lung cancer. Large Cell Neuroendocrine Carcinoma (LCNEC) is a subtype of Non-Small Cell Lung Cancer (NSCLC) and accounts for approximately 1.6% to 3.1% of all lung cancer. LCNEC is now recognized as a histologically high-grade non-small cell carcinoma by WHO, categorized as a variant of large cell carcinoma. It has a distant metastasis rate of 65% and poor prognosis even in early stages, with survival rates similar to Small-Cell Lung Carcinomas (SCCs). The life expectancy of stage IV LCNEC with distant metastasis was estimated at around 6 months.
We report a case of 49 years old male with carcinoma lung harboring LCNEC histology, who responded very well to Anti-EGFR TKI Gefitinib with a PFS of 14 months and ongoing with a partial response to disease.
Patil PP, Gupta VG, Rangaraju RR, Abbas W, Bajpai P, Aggarwal A. Large Cell Neuroendocrine Carcinoma of Lung with Synchronous Dual Activating EGFR Mutation and ALK Rearrangement - A Case Report. Oncol Case Report J. 2020;3(1):1017..